---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-135082"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:42:04.765899+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Karyopharm cuts FY2023 revenue guidance on higher patient assistance; Q1 net loss narrows

## Summary
- Q1 total revenue $38.7M, XPOVIO net product revenue $28.3M flat YoY; net loss $34.1M ($0.30/sh) vs $41.4M loss YoY.
- FY2023 total revenue guidance lowered to $145-160M (from $160-175M); XPOVIO net product revenue now $110-125M due to increased patient assistance programs.
- Non-GAAP R&D and SG&A expense guidance reduced to $245-260M; cash runway reiterated to late 2025.
- Phase 1 selinexor+ruxolitinib in front-line MF: 83.3% SVR35 at wk12, 80% TSS50; Phase 3 planned 1H 2023.
- Eltanexor in Hr R/R MDS interim: median OS 8.7 months; UK marketing authorization granted for NEXPOVIO combo.

## SEC filing metadata
- accession: 0001193125-23-135082
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312523135082/0001193125-23-135082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312523135082/d236538d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-135082
- JSON: https://secwatch.observer/filing/0001193125-23-135082.json
- Plain text: https://secwatch.observer/filing/0001193125-23-135082.txt

## Key facts
- Earnings Releases
  Karyopharm Therapeutics Inc. reported First Quarter 2023 results: revenue $38.7 Million.
  - Period: First Quarter 2023
  - Revenue: $38.7 Million
  - Result: reported results
  source text: Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress – Achieved First Quarter 2023 Total Revenues of $38.7 Million, including XPOVIO ® (selinexor) Net Product Revenue of $28.3 Million, Adversely Impacted by Increased Utilization of Patient Assistant Programs (PAP) and Higher Gross to Net; YoY Growth in Total Demand 1
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312523135082/0001193125-23-135082-index.htm
- Earnings Releases
  Karyopharm Therapeutics Inc. reported Full Year 2023 results: revenue $145 Million to $160 Million. Guidance lowered.
  - Period: Full Year 2023
  - Revenue: $145 Million to $160 Million
  - Guidance: lowered
  - Result: guidance update
  source text: Company Revises Full Year 2023 Total Revenue Guidance to $145 Million to $160 Million, Including Revised XPOVIO Net Product Revenue Guidance of $110 Million to $125 Million, Reflecting Increased Use of PAP – – Non-GAAP R&D and SG&A Expense Guidance Revised to $245 Million to $260 Million; Company Re-iterates Cash Runway to Late 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312523135082/0001193125-23-135082-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.